Price T Rowe Associates Inc Summit Therapeutics Inc. Transaction History
Price T Rowe Associates Inc
- $869 Billion
- Q3 2024
A detailed history of Price T Rowe Associates Inc transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 5,439,657 shares of SMMT stock, worth $112 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
5,439,657
Previous 2,042,100
166.38%
Holding current value
$112 Million
Previous $15.9 Million
647.83%
% of portfolio
0.01%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding SMMT
# of Institutions
201Shares Held
76.3MCall Options Held
2.01MPut Options Held
2.83M-
Baker Bros. Advisors LP New York, NY24.4MShares$501 Million5.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.9MShares$224 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$162 Million0.0% of portfolio
-
State Street Corp Boston, MA3.47MShares$71.1 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.1MShares$63.5 Million0.01% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $4.12B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...